EXAGEN DIAGNOSTICS ($XGN) posted quarterly earnings results on Monday, May 5th. The company reported earnings of -$0.20 per share, beating estimates of -$0.20 by $0.00. The company also reported revenue of $15,500,000, beating estimates of $14,688,763 by $811,237.
You can see Quiver Quantitative's $XGN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EXAGEN DIAGNOSTICS Insider Trading Activity
EXAGEN DIAGNOSTICS insiders have traded $XGN stock on the open market 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $XGN stock by insiders over the last 6 months:
- CO-INVESTMENT FUND, L.P. NMSIC has made 0 purchases and 2 sales selling 550,000 shares for an estimated $1,815,040.
- JOHN ABALLI (President and CEO) purchased 24,305 shares for an estimated $68,297
- JEFFREY G. BLACK (Chief Financial Officer) purchased 22,298 shares for an estimated $66,448
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EXAGEN DIAGNOSTICS Hedge Fund Activity
We have seen 16 institutional investors add shares of EXAGEN DIAGNOSTICS stock to their portfolio, and 18 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TORONTO DOMINION BANK added 891,366 shares (+inf%) to their portfolio in Q4 2024, for an estimated $3,654,600
- WASATCH ADVISORS LP removed 447,230 shares (-91.2%) from their portfolio in Q4 2024, for an estimated $1,833,642
- DRIEHAUS CAPITAL MANAGEMENT LLC added 418,505 shares (+inf%) to their portfolio in Q4 2024, for an estimated $1,715,870
- STONEPINE CAPITAL MANAGEMENT, LLC removed 283,349 shares (-53.0%) from their portfolio in Q4 2024, for an estimated $1,161,730
- HUNTLEIGH ADVISORS, INC. removed 71,169 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $255,496
- PERKINS CAPITAL MANAGEMENT INC removed 35,150 shares (-7.7%) from their portfolio in Q4 2024, for an estimated $144,115
- RENAISSANCE TECHNOLOGIES LLC removed 20,064 shares (-11.4%) from their portfolio in Q4 2024, for an estimated $82,262
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EXAGEN DIAGNOSTICS Analyst Ratings
Wall Street analysts have issued reports on $XGN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 11/12/2024
To track analyst ratings and price targets for EXAGEN DIAGNOSTICS, check out Quiver Quantitative's $XGN forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
